- Home
- DGLY vs APVO Comparison
DGLY vs APVO Comparison
Compare DGLY & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGLY
- APVO
- Stock Information
- Founded
- DGLY 2004
- APVO 2016
- Country
- DGLY United States
- APVO United States
- Employees
- DGLY N/A
- APVO N/A
- Industry
- DGLY Radio And Television Broadcasting And Communications Equipment
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- DGLY Technology
- APVO Health Care
- Exchange
- DGLY Nasdaq
- APVO Nasdaq
- Market Cap
- DGLY 4.2M
- APVO 4.1M
- IPO Year
- DGLY N/A
- APVO N/A
- Fundamental
- Price
- DGLY $2.47
- APVO $4.95
- Analyst Decision
- DGLY
- APVO Strong Buy
- Analyst Count
- DGLY 0
- APVO 1
- Target Price
- DGLY N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- DGLY 1.3M
- APVO 393.8K
- Earning Date
- DGLY 05-21-2025
- APVO 05-14-2025
- Dividend Yield
- DGLY N/A
- APVO N/A
- EPS Growth
- DGLY N/A
- APVO N/A
- EPS
- DGLY N/A
- APVO N/A
- Revenue
- DGLY $18,596,715.00
- APVO N/A
- Revenue This Year
- DGLY N/A
- APVO N/A
- Revenue Next Year
- DGLY N/A
- APVO N/A
- P/E Ratio
- DGLY N/A
- APVO N/A
- Revenue Growth
- DGLY N/A
- APVO N/A
- 52 Week Low
- DGLY $1.93
- APVO $4.30
- 52 Week High
- DGLY $320.00
- APVO $658.60
- Technical
- Relative Strength Index (RSI)
- DGLY 23.18
- APVO 28.32
- Support Level
- DGLY $2.23
- APVO $4.30
- Resistance Level
- DGLY $2.73
- APVO $5.18
- Average True Range (ATR)
- DGLY 0.59
- APVO 1.22
- MACD
- DGLY 3.20
- APVO 0.72
- Stochastic Oscillator
- DGLY 16.17
- APVO 6.47
About DGLY Digital Ally Inc.
Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.